NR3C2 and heart failure: Pharmacological treatment at discharge was also analyzed including antiplatelet- and heart failure-focused therapy (beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, mineralocorticoid receptor antagonists, diuretics).